Home
COPD: Novel Therapeutics and Management Strategies
22 October - 23 October 2012
COPD: Novel Therapeutics and Management Strategies

SAE Media Group are proud to present their 4th annual COPD: Novel Therapeutics and Management Strategies conference convening in Central London on Monday 22nd and Tuesday 23rd 2012. Consisting of an industry led programme with academic keynote presentations, this event will be the perfect opportunity to hear presentations on the latest hot topics surrounding COPD and to network with key industry professionals. This conference continues to promote increased awareness of COPD and explores ways to improve quality of life for patients, prevention of exacerbations and analyses the new treatment techniques developed over the previous twelve months.

SAE Media Group's 4th annual conference on COPD will provide attendees with a complete view of the field and will focus on novel combination therapies, the latest insights in drug developments and clinical trial design, as well as discussing health economics of COPD drugs. This informative event will bring together key opinion leaders in the field to provide attendees with an in-depth look into current advances in COPD. This year's agenda will provide an unparalleled opportunity for debate and problem solving of key challenges currently facing the field, allowing attendees to discuss progress in the area and exchange ideas moving forward, ensuring a truly comprehensive treatment of the most important issues.

FEATURED SPEAKERS

Sebastian Johnston

Sebastian Johnston

Professor of Respiratory Medicine, Imperial School Of Medicine London

Christine Tiesler

Associate Director, Late Stage Research, PPD Development GmbH & Co.KG
Christine Tiesler

Daniel Bock

Chief Scientific Officer, Revotar Biopharmaceuticals
Daniel Bock

Edwin Chilvers

Professor of Respiratory Medicine, University of Cambridge School of Clinical Medicine
Edwin Chilvers

Emma Baker

Professor of Clinical Pharmacology, St George's, University of London
Emma Baker

Emma Hickman

Research Investigator, Novartis
Emma Hickman

Ewan Walters

Medical Director, Teva UK Ltd
Ewan Walters

Frank Thielmann

Operational Lead, Inhalation New Solids, Novartis Pharma AG
Frank Thielmann

Geoff Down

Chief Medical Officer, Prosonix Ltd
Geoff Down

John Hurst

Senior Clinical Lecturer, Honorary Consultant, University College London
John Hurst

Jonathan Pritchard

Business Development Manager, Clinical Trials, Vitalograph
Jonathan Pritchard

Kelly Burrowes

EPSRC Post-Doctoral Research Fellow, University Of Oxford
Kelly Burrowes

Kevin Bacon

Chief Scientific Officer, Axikin
Kevin Bacon

Louise Donnelly

Reader in Respiratory Cell Biology, National Heart and Lung Institute Imperial College
Louise Donnelly

Magnus Nord

Director Safety Science, Associate Professor, AstraZeneca
Magnus Nord

Matthew Catley

Team Leader R and I, AstraZeneca
Matthew Catley

Nabil Jarad

Consultant Respiratory Physician, Bristol Royal Infirmary
Nabil Jarad

Paola Casarosa

Global Head Business Development and Licensing Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG
Paola Casarosa

Sabine Häußermann

Director Business Development, Inamed GmbH
Sabine Häußermann

Sebastian Johnston

Professor of Respiratory Medicine, Imperial School Of Medicine London
Sebastian Johnston

William Macnee

Professor of Respiratory and Environmental Medicine, University of Edinburgh
William Macnee

Wisia Wedzicha

Professor of Respiratory Medicine, University College London
Wisia Wedzicha

This event will act as a unique platform to hear from and discuss with key experts in the field on the key issues such as inflammatory drugs in COPD, Combination Therapies, Computational Modelling and Strategies for Bacterial Infections.

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Welcome and Introductions

clock

9:10

Overview of developing inhalation devices for COPD

• Developing techniques in inhalation device design
• Strategies to make the development process more efficient
• Overcoming common challenges in device development

clock

9:50

Case Study -Inhalation devices for generic products in the EU and the US

• Problems encountered
• How were these obstacles overcome
• What the future holds

clock

10:30

Morning Coffee

clock

11:00

Application / Inhalation devices in clinical trials and in practice

• Clinical Trial design analysis
• Information on the specifics of clinical trials for inhaled drugs

clock

11:50

Discussion Session

clock

12:15

Close of Workshop

clock

13:00

Registration & Coffee

clock

13:30

Welcome & Introductions

clock

13:45

Overview of Biomarkers for Efficacy

clock

14:15

Overview of Biomarkers for Safety

clock

14:45

Afternoon Tea

clock

15:00

Challenges in Biomarker Development in the respiratory field - COPD

  • Circulating biomarkers
  • Imaging as biomarker?
  • Validation challenges, and reasons to collaborate
  • clock

    16:00

    Challenges in Biomarker Development in the Respiratory Field - Drug-Induced Interstitial Lung Disease

  • Strategies for discovery
  • Imaging vs circulating biomarkers
  • Challenges in clinical qualification
  • clock

    17:00

    Discussion Session

    clock

    17:30

    Close of Workshop

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Sebastian Johnston

    Sebastian Johnston, Professor of Respiratory Medicine, Imperial School Of Medicine London

    clock

    9:10

    Current overview of the COPD field

    Sebastian Johnston

    Sebastian Johnston, Professor of Respiratory Medicine, Imperial School Of Medicine London

  • Mechanisms of exacerbations of COPD
  • Novel treatment strategies
  • What does the future hold in terms of drug development
  • clock

    9:50

    Anti-inflammatory drugs in COPD

    Daniel Bock

    Daniel Bock, Chief Scientific Officer, Revotar Biopharmaceuticals

  • Rationale and unmet needs
  • Potential benefits: from prevention to restructuring
  • Challenges in drug development: how to translate into clinical benefit?
  • clock

    10:25

    Morning Coffee

    clock

    10:45

    Immunology of COPD

  • Innate immune responses
  • Adaptive immune responses
  • Comparing and contrasting different responses
  • Loss of regulation
  • Matthew Catley

    Matthew Catley, Team Leader R and I, AstraZeneca

    clock

    11:25

    RC-Kinase; a novel target implicated in COPD

    Kevin Bacon

    Kevin Bacon, Chief Scientific Officer, Axikin

    • Effects of small molecule inhibitors in mouse models of smoke-induced inflammation and fibrosis
    • Identification and characterization of a novel COPD-relevant kinase
    • Immune mechanisms
    • Generation of small molecule inhibitors and characterization in smoking, fibrosis and oncology models relevant to COPD and its co-morbidities

    clock

    12:00

    Measuring neutrophil kinetics in COPD

    Edwin Chilvers

    Edwin Chilvers, Professor of Respiratory Medicine, University of Cambridge School of Clinical Medicine

  • Use or radiolabelled neutrophils to quantify lung inflammation
  • Kinetics and fate of circulating neutrophils in man
  • Early studies of intravascular kinetics and fate of human eosinophils
  • Opportunity to use radiolabelled inflammatory cells to perform proof of principle therapeutic trials
  • clock

    12:35

    Networking Lunch

    clock

    13:45

    Effective management of COPD

    Ewan Walters

    Ewan Walters, Medical Director, Teva UK Ltd

  • What are the burdens to society, the patient and to the economy?
  • What is the root of these problems
  • Computer guided diagnosis and treatment algorithms
  • Lessons from Asthma that we can use in COPD
  • clock

    14:25

    Clinical trial design considerations

    Christine Tiesler

    Christine Tiesler, Associate Director, Late Stage Research, PPD Development GmbH & Co.KG

     

    • Understanding current clinical trial guidelines for COPD
    • Are exacerbations the most relevant outcome parameters in COPD clinical trials
    • Long term observations
    • Short term studies
    clock

    15:05

    Afternoon Tea

    clock

    15:25

    Novel strategies in exacerbation management

    William Macnee

    William Macnee, Professor of Respiratory and Environmental Medicine, University of Edinburgh

    • Exacerbation definitions
    • Impact of exacerbations
    • Exacerbation prevention
    • Treatment of exacerbations
    clock

    16:05

    Computational modelling of the lung: towards understanding asthma and COPD

    Kelly Burrowes

    Kelly Burrowes, EPSRC Post-Doctoral Research Fellow, University Of Oxford

  • Developing patient-specific computational models;
  • Introduction to the AirPROM AND Synergy-COPD European projects
  • Developing multi-scale computational models
  • Application of the models to understanding airway disease
  • clock

    16:40

    Glucose homeostasis: a target for prevention and treatment of exacerbations

    Emma Baker

    Emma Baker, Professor of Clinical Pharmacology, St George's, University of London

     

  • Airway and systemic glucose homeostasis in health and disease
  • Abnormal glucose homeostasis and COPD exacerbations
  • Therapeutic approaches and clinical trials
  • clock

    17:20

    Chairman's Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Wisia Wedzicha

    Wisia Wedzicha, Professor of Respiratory Medicine, University College London

    clock

    9:10

    Understanding COPD exacerbations

    Paola Casarosa

    Paola Casarosa, Global Head Business Development and Licensing Respiratory Diseases, Boehringer Ingelheim Pharma GmbH & Co. KG

  • Understanding exacerbation causes: clinical evidence for role of viruses, bacterias…
  • Pharmacological interventions which are effective for the reduction of exacerbation frequency and severity . Non-pharmacological therapies (such as pulmonary rehabilitation, and home ventilatory support)
  • The future of exacerbation prevention: what is in the pipeline?
  • clock

    9:50

    Managing exacerbations of COPD

    Wisia Wedzicha

    Wisia Wedzicha, Professor of Respiratory Medicine, University College London

  • Guidelines for COPD exacerbation prevention
  • Novel bronchodilator approaches for exacerbation prevention
  • Combination therapy with ICS and exacerbation prevention
  • Phosphodiesterase inhibitors eg roflumilast and other anti-inflammatory therapy
  • Can managing the acute exacerbation affect exacerbation frequency
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Targeting exacerbations of COPD

    Emma Hickman

    Emma Hickman, Research Investigator, Novartis

  • Brief overview of exacerbations
  • Developing pre-clinical models of acute COPD exacerbations
  • Limitations of pre-clinical models
  • Looking to the future for treating exacerbations 
  • clock

    11:40

    COPD and Co-morbidities

    John Hurst

    John Hurst, Senior Clinical Lecturer, Honorary Consultant, University College London

  • An NHS viewpoint
  • What tools are currently available to us?
  • Exploring methods to prevent exacerbations in COPD
  • clock

    12:20

    Bronchiectasis in patients with COPD

    Nabil Jarad

    Nabil Jarad, Consultant Respiratory Physician, Bristol Royal Infirmary

  • An NHS viewpoint 
  • What tools are currently available to us?
  • Exploring methods to prevent exacerbations in COPD 
  • clock

    13:00

    Networking Lunch

    clock

    14:00

    From molecule to medicine – obstacles on the way from discovery to market

  • Oral or inhaled? developability assessment of new compounds in the treatment of COPD
  • Physical properties and stability – a good drug doesn´t always make a good product
  • DPI, MDI or nebuliser? Selection criteria from the products point of view
  • Manufacturing challenges for inhaled drug products
  • The future of development and manufacturing of inhaled products
  • Frank Thielmann

    Frank Thielmann, Operational Lead, Inhalation New Solids, Novartis Pharma AG

    clock

    14:35

    Translational Biomarkers in Respiratory Diseases – What They Can Deliver

    Magnus Nord

    Magnus Nord, Director Safety Science, Associate Professor, AstraZeneca

  • Current developments in Safety Biomarkers - definitions and key principles
  • Obstacles in Safety Biomarker development, validation and clinical qualification
  • Imaging vs circulation biomarkers in clinical drug safety
  • Case studies of Safety Biomarker applications in COPD drug development and beyond
  • clock

    15:10

    Afternoon Tea

    • Developments in inflammation in airways disease
    • Choosing novel targets
    • Novel effective antagonists
    • Current trials of novel antagonists

    clock

    15:40

    Novel antagonists to prevent airway inflammation

    Louise Donnelly

    Louise Donnelly, Reader in Respiratory Cell Biology, National Heart and Lung Institute Imperial College

  • Developments in inflammation in airways disease
  • Choosing novel targets
  • Novel effective antagonists
  • Current trials of novel antagonists
  • clock

    16:15

    Combination therapies in COPD

    Geoff Down

    Geoff Down, Chief Medical Officer, Prosonix Ltd

  • Unmet needs in the management of COPD patients
  • Scientific rationale for combination therapies
  • Delivering inhaled combination therapy
  • Discussion into future developments in the field
  • clock

    16:50

    Chairman’s Closing Remarks and Close of Day Two


    Operational Lead, Inhalation New Solids
    Novartis Pharma AG
    Medical Director
    Teva UK Ltd
    Team Leader R and I
    AstraZeneca
    Professor of Respiratory Medicine
    University College London
    Research Investigator
    Novartis
    Chief Medical Officer
    Prosonix Ltd
    Director Safety Science, Associate Professor
    AstraZeneca
    Global Head Business Development and Licensing Respiratory Diseases
    Boehringer Ingelheim Pharma GmbH & Co. KG
    Reader in Respiratory Cell Biology
    National Heart and Lung Institute Imperial College
    Professor of Respiratory Medicine
    University of Cambridge School of Clinical Medicine
    Professor of Respiratory Medicine
    Imperial School Of Medicine London
    Senior Clinical Lecturer, Honorary Consultant
    University College London
    Chief Scientific Officer
    Axikin
    Chief Scientific Officer
    Revotar Biopharmaceuticals
    Professor of Clinical Pharmacology
    St George's, University of London
    Consultant Respiratory Physician
    Bristol Royal Infirmary
    Professor of Respiratory and Environmental Medicine
    University of Edinburgh
    Associate Director, Late Stage Research
    PPD Development GmbH & Co.KG
    EPSRC Post-Doctoral Research Fellow
    University Of Oxford
    Business Development Manager, Clinical Trials
    Vitalograph
    Director Business Development
    Inamed GmbH

    Workshops

    Inhalation Device Development

    Inhalation Device Development

    Copthorne Tara Hotel
    24 October 2012
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.